Health Care [ 5/12 ] | Biotechnology [ 51/74 ]
NASDAQ | Common Stock
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes.
Forte Biosciences, Inc. is headquartered in Dallas, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 1, 26 | -1.24 Increased by +9.49% | -1.16 Decreased by -6.90% |
| Dec 31, 25 | -1.45 Decreased by -23.93% | -1.15 Decreased by -26.36% |
| Nov 14, 25 | -0.99 Increased by +78.19% | -0.08 Decreased by -1.14 K% |
| Aug 14, 25 | -0.96 Decreased by -255.56% | -1.11 Increased by +13.51% |
| May 15, 25 | -1.37 Decreased by -756.25% | -0.89 Decreased by -53.93% |
| Mar 28, 25 | -1.17 Decreased by -515.79% | -0.14 Decreased by -735.71% |
| Nov 14, 24 | -4.54 Decreased by -1.65 K% | -7.12 Increased by +36.24% |
| Aug 14, 24 | -0.27 Increased by +35.71% | -0.17 Decreased by -58.82% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 0.00 Decreased by N/A% | -22.14 M Decreased by -41.39% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 25 | 0.00 Decreased by -100.00% | -24.79 M Decreased by -246.44% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -17.68 M Decreased by -110.70% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -11.25 M Increased by +10.09% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by -100.00% | -15.66 M Decreased by -111.00% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 38.00 K Increased by +533.33% | -7.16 M Decreased by -21.85% | Decreased by -18.83 K% Increased by +80.76% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -8.39 M Increased by +15.70% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -12.51 M Decreased by -40.64% | Decreased by N/A% Decreased by N/A% |